LYRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Lyra Therapeutics Inc (LYRA) is not a good buy for a beginner investor with a long-term strategy at this time. The stock exhibits weak financial performance, bearish technical indicators, and lacks positive catalysts or trading signals to support an immediate investment decision.
The stock is in a bearish trend with moving averages indicating downward momentum (SMA_200 > SMA_20 > SMA_5). RSI at 17.989 suggests the stock is oversold, but the MACD histogram is positively contracting at 0.0333. Key support levels are at 1.188 and 1.094, with resistance at 1.341 and 1.494.
NULL identified. No recent news, no significant hedge fund or insider activity, and no congress trading data.
Additionally, the stock lacks any significant trading trends or positive sentiment indicators.
In Q3 2025, revenue dropped to $25,000 (-87.18% YoY), net income dropped to -$5,984,000 (-49.60% YoY), and EPS dropped to -3.38 (-62.73% YoY). Gross margin remained flat at 100%.
No data available for analyst ratings or price target changes.
